Navigation Links
Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
Date:1/12/2012

SAN DIEGO, Jan. 12, 2012 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease. MP4CO is designed to deliver therapeutic levels of carbon monoxide (CO) to patients suffering from a sickle cell crisis. This initial study will involve patients who are not currently undergoing a painful vaso-occlusive crisis. Preclinical studies show that carbon monoxide stabilizes the hemoglobin of patients with sickle cell disease and prevents the sickling of red blood cells.

"We are encouraged by the preclinical data on MP4CO and look forward to evaluating the safety and potential efficacy of this therapy in helping alleviate pain associated with a sickle cell crisis, while also potentially reducing the severity and duration of a crisis," said Dr. Jo Howard, at Guy's and St Thomas' Hospital, London, UK. "There is currently a dearth of treatments for painful vaso-occlusive crises associated with sickle cell disease, and MP4CO represents a potential treatment option for these patients."

The clinical trial is a multi-center, randomized, double-blind, controlled study that will enroll approximately 32 clinically stable adult patients with sickle cell disease who are not undergoing a painful vaso-occlusive crisis. The trial will be conducted at four sites across three countries, including the United Kingdom, France and Jamaica. The primary objective of the study is to establish the safety of treatment with MP4CO. The study will comprise ascending dose levels in five groups of single dose infusions followed by three groups of fractionated doses.

"This trial initiation is a key step towards providing a treatment to patie
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
2. Sangart Announces Closing of $50 Million Series G Financing
3. Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
4. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
5. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
6. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
7. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
9. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... REYKJAVIK, Iceland, July 1 The ... several new common,single-letter variants in the sequence of the human ... a multinational consortium of scientists,led by a team from deCODE ... 50,000 patients and control participants from fourteen countries.,It is published ...
... announces that it has reached the halfway mark (1,600 patients) ... G auging R esponsiveness with A V erifyNow(R) ... nd S afety). The trial is specifically designed ... for patients who are poor responders to clopidogrel (Plavix(R)). ...
Cached Medicine Technology:deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
(Date:10/20/2014)... D.C. (PRWEB) October 20, 2014 Zereana Jess-Huff, ... crowned Mrs. Maryland 2014 on a platform to think outside ... scars, and uses her position to raise awareness about women’s ... awareness for breast cancer. You say the color pink and ... I know for a fact that it has not been ...
(Date:10/20/2014)... Kennewick, WA (PRWEB) October 20, 2014 ... new workflow management software application. The new module ... ensure patients receive full life-cycle quality care. , This ... to others within their practice, attach a to-do item ... see fit, and even set up reoccurring reminders for ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2
... IQ for HealthVault Empowers Patients to Orchestrate Health ... ... Kryptiq, the leading provider,of next generation healthcare connectivity solutions, ... offices,and patients using Microsoft(R) HealthVault(TM), at the 2008 HIMSS,(Healthcare Information ...
... Calif., Feb. 25 Hyperion,Therapeutics, Inc. today announced ... Phase 2 clinical trial of AMMONUL(R) (sodium phenylacetate ... III or IV hepatic,encephalopathy (HE). The randomized, double-blind ... of AMMONUL versus standard of care in,hospitalized adults. ...
... CHARLOTTE, N.C., Feb. 25 MedCath Corporation,(Nasdaq: MDTH ... at the Raymond James 29th Annual Institutional Investors,Conference held ... Orlando,Fla., MedCath,s senior management will give its presentation ... will be web cast live over the Internet,via MedCath,s ...
... 25 Omron Healthcare, Inc. has,announced Bob ... officer. With,an extensive background in sales, Kondraske ... profit growth in their mainstay business,categories: blood ... medical. Kondraske,s experience as a proven,business leader ...
... Va., Feb. 25 Meddius, an emerging,provider ... integration technology and professional services to assist ... system,which provides hospitals with a Web-based, automated ... associated infections (HAIs). The announcement,was made today ...
... enhanced to support multifaceted hospital, environments; provide more secure ... ... Feb. 25 HIMSS ,08 -- Omnicell,Inc. (Nasdaq: ... acute,healthcare facilities, today introduced its OptiFlex(TM) SS 9.0 supply,chain ...
Cached Medicine News:Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 3Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 2Health News:Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy 3Health News:Omron Healthcare Names New Chief Operating Officer Bob Kondraske 2Health News:Meddius Signs Agreement to Deliver an Integration Platform for Premier's SafetySurveillor(TM) 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 2Health News:Hospital Environments Increase Staff Efficiency and Patient Safety With Omnicell OptiFlex(TM) SS 9.0 3
... The LT-Cage device ... balance with significantly less ... endplates. Medtronic Sofamor Danek's ... designed to easily and ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Designed for the effective positioning of patients during spinal surgery, the frame gives the surgeon a remarkably simple and versatile surgical tool....
Adjust-A-Tip cautery....
Medicine Products: